Ambrosia vs Cortellis — Deal Benchmarking Compared

Which Tool Gives You Better Deal Intelligence?

1,500+ curated biopharma deals with 1,535 unique data points on one side; a legacy Clarivate intelligence platform built on clinical trial and regulatory data on the other. If you are a BD professional benchmarking a licensing deal, evaluating an earn-out structure, or modeling risk-adjusted NPV for a board presentation, the choice between Ambrosia and Cortellis is not cosmetic — it determines whether you walk into a negotiation with a spreadsheet or a simulation.

This comparison is written for the people who actually use these tools: directors of business development, VP-level dealmakers, biotech CFOs, and investors running diligence on asset-level transactions. We will be fair, factual, and specific. Where we lack verified data on Cortellis, we will say so.

Overview — What Each Tool Does

Ambrosia

Ambrosia is a deal-intelligence platform purpose-built for biopharma transaction benchmarking and valuation. Its core offering is 14 real-time benchmarking engines — including rNPV, Monte Carlo simulation, Real Options via CRR lattice, Tornado Sensitivity, Partner Matching across 850+ companies, Pharma Intent Score, Deal Waterfall, Scenario Comparison, Competitive Dynamics, Lifecycle Extensions, Buyer-Specific Valuation, Market Sizing, Competitive Landscape, and standard Deal Terms analysis. The database covers 1,500+ deals across 12 therapeutic areas and 562 indications, with roughly 280 unique curated comparable deals available for side-by-side benchmarking.

Cortellis

Cortellis, owned by Clarivate Analytics, is a broad life-sciences intelligence suite. Its strength is clinical trial tracking, regulatory intelligence, pipeline analysis, and competitive monitoring. Cortellis Deals Intelligence, a module within the broader platform, aggregates deal records — licensing agreements, M&A, co-development arrangements — and provides filtering by therapeutic area, deal type, phase, and geography. Based on publicly available information, Cortellis indexes tens of thousands of deal records sourced from SEC filings, press releases, and proprietary research. Its primary user base includes competitive intelligence teams, portfolio strategists, and R&D planners who need pipeline context alongside deal data.

Feature Comparison

Data Depth

This is where the Cortellis alternative conversation gets pointed. Cortellis aggregates a large volume of deal records. If you need to answer "how many oncology licensing deals closed in 2024," it will return a list. But volume is not depth. The question BD professionals should ask is: does the platform give me upfront payments, milestone breakdowns by type (regulatory, commercial, sales-based), royalty tiers, option structures, and equity components — deal by deal?

Ambrosia's 1,535 unique data points across 1,500+ deals are structured specifically for this. Each of the ~280 curated comparable deals includes granular financial terms: upfront cash, near-term milestones, total biobucks, royalty ranges, and deal structure metadata (exclusive vs. co-exclusive, territory splits, opt-in/opt-out rights). This is the difference between a database that tells you a deal happened and one that tells you what the deal actually looked like on the term sheet.

Cortellis provides deal summaries and, in many cases, disclosed financial terms pulled from SEC filings and press releases. For large, publicly disclosed transactions, this data can be useful. However, based on publicly available information, Cortellis does not appear to offer native computational engines that process these terms into rNPV models, waterfall analyses, or Monte Carlo distributions in real time. The user exports data and builds models offline — or licenses additional Clarivate modules.

For a BD director preparing a deal-terms memo for a $200M licensing negotiation, the difference between "here are 50 comparable deal headlines" and "here is a Monte Carlo distribution of upfront-to-total-deal ratios across 280 comparables in your indication" is the difference between a starting point and an answer.

Pricing

Ambrosia Pro is $299/month, or $199/month on an annual plan. A one-time benchmarking report is $499. This pricing is publicly listed and accessible to individual BD professionals, small biotechs, and boutique advisory firms — not just enterprise procurement teams.

Cortellis does not publicly list pricing. Based on industry sources and user reports, Cortellis subscriptions typically range from $30,000 to $80,000+ per year depending on modules selected, number of seats, and institutional negotiation. Some academic and smaller organizations access Cortellis through institutional licenses at lower tiers, but the Deals Intelligence module with full functionality is generally an enterprise commitment.

The math is straightforward. A single Ambrosia Pro annual subscription costs ~$2,388/year. Even a conservative Cortellis estimate is 12–30x that figure. For a large pharma BD team that already subscribes to Clarivate's broader suite for clinical trial tracking, adding the deals module may be incremental. For a 15-person biotech or a solo BD consultant, Ambrosia's pricing removes the access barrier entirely.

Who Each Tool Is Best For

Choose Cortellis if:

• Your primary need is clinical trial intelligence and regulatory tracking with deal data as a secondary input.
• You are part of a large pharma organization that already has a Clarivate enterprise agreement and wants a single-vendor ecosystem for pipeline, patent, and deal data.
• Your competitive intelligence team needs broad pipeline landscaping with deal context layered on top — not deep deal-term analytics.

Choose Ambrosia if:

• You need to benchmark deal terms in real time — upfront, milestones, royalties, structure — with computational engines that go beyond static tables.
• You are building board-ready valuations and need native rNPV, Monte Carlo, Real Options, and sensitivity analysis without exporting to Excel.
• You are a biotech founder, BD lead, or investor who needs deal intelligence at a price point that does not require a six-figure procurement cycle.
• Partner identification matters: the 850+ company Partner Matching engine and Pharma Intent Score are capabilities that do not have direct equivalents in Cortellis's publicly documented feature set.

Verdict

Cortellis is a strong platform for what it was designed to do: comprehensive life-sciences intelligence anchored in clinical, regulatory, and pipeline data. If your workflow starts with "which assets are in Phase 2 for NASH" and ends with "who has licensed in this space," Cortellis delivers. It is the incumbent for a reason.

But if your workflow starts with "what should the upfront be for a Phase 2 oncology asset with a specific target, indication, and competitive set" — and ends with a risk-adjusted valuation model you can defend in a board meeting — Ambrosia is the sharper tool. Fourteen engines versus a filterable deal database is not a close comparison for transaction-focused work. The 562-indication coverage across 12 TAs, the ~280 curated comparables with 1,535 data points, and the sub-$300/month price point make Ambrosia the most compelling Cortellis alternative for BD professionals whose job is to structure, negotiate, and close deals.

Neither platform replaces the other entirely. Cortellis covers pipeline intelligence that Ambrosia does not attempt. Ambrosia covers deal analytics depth that Cortellis does not match. The question is which gap is more expensive to leave open — and for anyone on the transaction side of biopharma, the answer is deal benchmarking.

See it for yourself. Run a benchmark on your asset's therapeutic area and phase right now — no enterprise contract required. Try the Calculator or explore curated comparables in the Deal Benchmarks library.